{"id":389,"date":"2022-07-14T18:52:00","date_gmt":"2022-07-14T18:52:00","guid":{"rendered":"https:\/\/fertiga.com\/?p=389"},"modified":"2025-11-03T08:09:57","modified_gmt":"2025-11-03T08:09:57","slug":"fertiga-at-the-38th-annual-eshre-meeting-in-milan","status":"publish","type":"post","link":"https:\/\/fertiga.com\/fr\/news\/fertiga-at-the-38th-annual-eshre-meeting-in-milan\/","title":{"rendered":""},"content":{"rendered":"\n
\n\n \n
\n \"LinkedIn\n \n \n
\n July 2022\n <\/div>\n\n
\n

Fertiga at the 38th annual ESHRE meeting in Milan<\/h3>\n \n

\n In July 2022, Fertiga attended the 38th annual ESHRE meeting (European Society of Human Reproduction and Embryology) in Milan to present its latest results. The poster was titled\u00a0“Cumulus cell analysis as a non-invasive oocyte selection strategy to reduce the number of oocytes\/embryos cultured and increase pregnancy rates”.\n <\/p>\n\n \n

\n The Aurora Test is a predictor of the most competent embryo. Generally, the test has been used to select transferable Day-3 embryos. A retrospective analysis of Van Vaerenbergh et al. (2021) investigated whether the Aurora Test could also be applied to select oocytes on Day 1. Therefore, a subset of 80 patients was selected. On average, these patients had 8 large pre-ovulatory follicles on trigger day and at least 4 2PN oocytes. The team then studied the effect of processing only the three highest-ranking oocytes with the Aurora Test. These were then compared to the processing of all oocytes.\n <\/p>\n\n \n

\nThe study concludes that cumulus cell analysis may reduce culture work and improve the outcome in ICSI eSET. By performing the Aurora Test, patients benefit from a higher pregnancy rate in the fresh transfer cycle. The oocyte selection strategy results in a reduction of embryo culture and evaluation work.\n <\/p>\n\n

\n \n Read more\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n\n<\/div>\n\n\n